1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Valuation
Discussion
Symbol
LIXT
Event Date
2020-11-25
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
1.2M
13.54M
$64.3M
8.9%
Implied Upside vs Midpoint
Description
—
LIXTE BIOTECHNOLOGY HOLDINGS, INC. annual income statement and balance sheet, FY 2020 to FY 2025, as reported in SEC filings.
| Metric | FY 2020 | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Operating income | ($3.3M) | ($6.7M) | ($3.6M) | ($5.1M) |
| Net income | ($3.3M) | ($6.7M) | ($3.6M) | ($6.1M) |
| Metric | FY 2020 | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Total assets | $5.2M | $5.1M | $1.1M | $12.7M |
| Total liabilities | — | — | $318K | $1.8M |
| Total equity | $5.0M | $4.8M | $827K | $11.0M |
| Cash & equivalents | $5.1M | $4.8M | $1.0M | $5.1M |